Walleye Capital
TGTX icon

Walleye Capital’s TG Therapeutics TGTX Stock Holding History

Walleye Capital’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$846K Sell
15,400
-11,300
-42% -$462K ﹤0.01% 2268
2026
Q1 		$887K Sell
26,700
-20,600
-44% -$614K ﹤0.01% 2187
2025
Q4 		$1.41M Buy
47,300
+13,100
+38% +$428K ﹤0.01% 2162
2025
Q3 		$1.24M Sell
34,200
-49,700
-59% -$1.64M ﹤0.01% 1935
2025
Q2 		$3.02M Buy
83,900
+9,200
+12% +$343K 0.01% 1203
2025
Q1 		$2.95M Buy
74,700
+23,200
+45% +$781K 0.01% 1158
2024
Q4 		$1.55M Buy
51,500
+30,500
+145% +$875K ﹤0.01% 2011
2024
Q3 		$491K Sell
21,000
-71,300
-77% -$1.56M ﹤0.01% 3313
2024
Q2 		$1.64M Buy
92,300
+30,700
+50% +$490K ﹤0.01% 2301
2024
Q1 		$937K Buy
61,600
+53,800
+690% +$857K ﹤0.01% 2655
2023
Q4 		$133K Sell
7,800
-21,700
-74% -$252K ﹤0.01% 3912
2023
Q3 		$247K Buy
29,500
+24,700
+515% +$344K ﹤0.01% 3393
2023
Q2 		$119K Buy
4,800
+1,100
+30% +$28.4K ﹤0.01% 3365
2023
Q1 		$55.6K Buy
+3,700
New +$56.2K ﹤0.01% 3175

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Walleye Capital's TGTX Position: Q2 2026 in Review

Walleye Capital increased its TG Therapeutics (TGTX) stake by 9,330% in Q2 2026, buying an estimated $7.71M and bringing the position to 190,302 shares worth $10.5M. The position accounts for 0.04% of the portfolio, ranked #459.

Walleye Capital first reported a position in TGTX in Q4 2019 and has held it in 14 quarters since. 430 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

  • Walleye Capital held 190,302 shares of TG Therapeutics worth $10.5M as of Q2 2026.
  • Walleye Capital bought 188,284 TG Therapeutics shares in Q2 2026, an estimated $7.71M.
  • TG Therapeutics made up 0.04% of Walleye Capital's portfolio in Q2 2026, its #459 holding.
  • Walleye Capital first reported a position in TG Therapeutics in Q4 2019 and has held it in 14 quarters since.
  • 430 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Walleye Capital's 13F filing for Q2 2026, filed 3 Aug 2026.